SSY Group (HKG:2005) expects a decline of between 45% and 60% in attributable profit for the year 2025 from HK$1.06 billion a year prior, according to a Monday Hong Kong bourse filing.

The pharmaceutical firm attributed the forecast to a lower terminal sales volume of medicines, continuing price pressure, and a drop in the turnover of Bromhexine Hydrochloride in ampoule injection.